gms | German Medical Science

44. Jahrestagung der Deutschen Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen e. V. (DGPRÄC), 18. Jahrestagung der Vereinigung der Deutschen Ästhetisch-Plastischen Chirurgen e. V. (VDÄPC)

12.09. - 14.09.2013, Münster

Article

Send article

Effects of TRAIL and TRD on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma

Meeting Abstract

Search Medline for

  • presenting/speaker Carmen Karlisch - Marienhospital Witten, Gynäkologie und Geburtshilfe, Witten, Deutschland
  • Kamran Harati - BG-Universitätsklinik Bergmannsheil, Plastische Chirurgie, Bochum, Deutschland
  • Ansgar Michael Chromik - Universitätsklinikum St. Josef Hospital, Allgemein- und Viszeralchirurgie, Bochum, Deutschland
  • Daniel Bulut - Universitätsklinikum St. Josef Hospital, Medizinische Klinik II, Bochum, Deutschland
  • Ludger Klein-Hitpass - Universität Duisburg-Essen, Zentrum für medizinische Biotechnologie, Essen, Deutschland
  • Marcus Lehnhardt - BG-Universitätsklinik Bergmannsheil, Plastische Chirurgie, Bochum, Deutschland
  • Waldemar Uhl - Universitätsklinikum St. Josef Hospital, Allgemein- und Viszeralchirurgie, Bochum, Deutschland
  • Adrien Daigeler - BG-Universitätsklinik Bergmannsheil, Plastische Chirurgie, Bochum, Deutschland

Deutsche Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen. Vereinigung der Deutschen Ästhetisch-Plastischen Chirurgen. 44. Jahrestagung der Deutschen Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen (DGPRÄC), 17. Jahrestagung der Vereinigung der Deutschen Ästhetisch-Plastischen Chirurgen (VDÄPC). Münster, 12.-14.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. DocP 90

doi: 10.3205/13dgpraec191, urn:nbn:de:0183-13dgpraec1916

Published: September 10, 2013

© 2013 Karlisch et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumours representing 1% of all malignancies in adults. Therapy for STS should be individualised and multimodal, but complete surgical resection with clear margins remains the mainstay of therapy. Disseminated soft tissue sarcoma still represents a therapeutic dilemma. Commonly used chemotherapeutic agents like doxorubicin and ifosfamide have proven to be effective in fewer than 30% in these cases. Therefore we tested the apoptotic and antiproliferative in vitro effects of TNF related apoptosis inducing ligand (TRAIL) and taurolidine (TRD) on rhabdomyosarcoma (A-204), leiomyosarcoma (SK-LMS-1), and epithelioid cell sarcoma (VA-ES-BJ) cell lines.

Methods: Viability, apoptosis and necrosis were quantified by FACS analysis (Propidiumiodide/AnnexinV staining). Gene expression was analysed by RNA Microarray and the results validated for selected genes by rtPCR. Protein level changes were documented by Western Blot analysis. Cell proliferation was analysed by BrdU ELISA assay.

Results: The single substances TRAIL and TRD significantly induced apoptotic cell death and decreased proliferation in rhabdomyosarcoma and epithelioid cell sarcoma cells. The combined use of TRAIL and TRD resulted in a synergistic apoptotic effect in all three cell lines, especially in rhabdomyosarcoma cells leaving 18% viable cells after 48 hours of incubation (p

Figure 1 [Fig. 1], Figure 2 [Fig. 2]

Conclusion: This in vitro study demonstrates that TRAIL and TRD synergise in inducing apoptosis and inhibiting proliferation in different human STS cell lines. Effects on Gene expression differ relevantly in the sarcoma entities. These results provide experimental support for in vivo trials assessing the effect of TRAIL and taurolidine in STS and sustain the approach of individualized therapy.